DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
DiaMedica Therapeutics (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025, at 11:20am Eastern Time.
The company specializes in developing novel treatments for severe ischemic diseases, with their lead candidate DM199 being the first pharmaceutically active recombinant form of the KLK1 protein. This therapeutic approach has established presence in Asia for treating acute ischemic stroke, preeclampsia, and other vascular diseases.
Investors interested in meeting with DiaMedica's management during the conference can arrange meetings through their Oppenheimer representative.
DiaMedica Therapeutics (Nasdaq: DMAC), una società biofarmaceutica in fase clinica, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulla Salute e le Scienze della Vita di Oppenheimer il 12 febbraio 2025, alle 11:20 ora orientale.
L'azienda si specializza nello sviluppo di nuovi trattamenti per malattie ischemiche severe, con il loro candidato principale DM199, che rappresenta la prima forma ricombinante attiva farmacologicamente della proteina KLK1. Questo approccio terapeutico ha una presenza consolidata in Asia per il trattamento dell'ictus ischemico acuto, della preeclampsia e di altre malattie vascolari.
Gli investitori interessati a incontrare il management di DiaMedica durante la conferenza possono organizzare incontri tramite il loro rappresentante di Oppenheimer.
DiaMedica Therapeutics (Nasdaq: DMAC), una empresa biofarmacéutica en etapa clínica, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer el 12 de febrero de 2025, a las 11:20 a.m. hora del este.
La compañía se especializa en el desarrollo de nuevos tratamientos para enfermedades isquémicas severas, siendo su candidato principal DM199 la primera forma recombinante farmacológicamente activa de la proteína KLK1. Este enfoque terapéutico tiene una presencia establecida en Asia para el tratamiento del accidente cerebrovascular isquémico agudo, la preeclampsia y otras enfermedades vasculares.
Los inversores interesados en reunirse con la dirección de DiaMedica durante la conferencia pueden organizar reuniones a través de su representante de Oppenheimer.
DiaMedica Therapeutics (Nasdaq: DMAC), 임상 단계의 생명공학 회사, 는 2025년 2월 12일 동부 표준시 기준 오전 11:20에 Oppenheimer 제35회 연례 헬스케어 생명과학 콘퍼런스에 참여할 것이라고 발표했습니다.
이 회사는 심각한 허혈성 질환에 대한 새로운 치료법 개발을 전문으로 하며, 그들의 주요 후보물질인 DM199는 KLK1 단백질의 첫 번째 약리 활성 재조합 형태입니다. 이 치료 접근법은 급성 허혈성 뇌졸중, 자간전증 및 기타 혈관 질환 치료를 위해 아시아에서 확고한 입지를 다졌습니다.
회의 중 DiaMedica 경영진과의 만남에 관심 있는 투자자는 Oppenheimer 대리를 통해 회의 일정을 조정할 수 있습니다.
DiaMedica Therapeutics (Nasdaq: DMAC), une entreprise bio-pharmaceutique en phase clinique, a annoncé sa participation à la 35e Conférence Annuelle sur la Santé et les Sciences de la Vie d'Oppenheimer le 12 février 2025 à 11h20, heure de l'est.
L'entreprise se spécialise dans le développement de nouveaux traitements pour les maladies ischémiques sévères, avec son principal candidat DM199 qui est la première forme recombinante active sur le plan pharmaceutique de la protéine KLK1. Cette approche thérapeutique est déjà bien établie en Asie pour le traitement des AVC ischémiques aigus, de la prééclampsie et d'autres maladies vasculaires.
Les investisseurs intéressés par une rencontre avec la direction de DiaMedica lors de la conférence peuvent organiser des réunions via leur représentant Oppenheimer.
DiaMedica Therapeutics (Nasdaq: DMAC), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 35. jährlichen Healthcare Life Sciences-Konferenz von Oppenheimer am 12. Februar 2025 um 11:20 Uhr Eastern Time angekündigt.
Das Unternehmen hat sich auf die Entwicklung neuartiger Behandlungen für schwere ischämische Krankheiten spezialisiert, wobei ihr Hauptkandidat DM199 die erste pharmazeutisch aktive rekombinante Form des KLK1-Proteins darstellt. Dieser therapeutische Ansatz hat sich in Asien zur Behandlung von akutem ischämischen Schlaganfall, Präeklampsie und anderen vaskulären Erkrankungen etabliert.
Investoren, die daran interessiert sind, während der Konferenz ein Treffen mit dem Management von DiaMedica zu arrangieren, können dies über ihren Oppenheimer-Vertreter tun.
- None.
- None.
Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Oppenheimer representative to arrange a meeting.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210075559/en/
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Source: DiaMedica Therapeutics Inc.
FAQ
When is DiaMedica Therapeutics (DMAC) presenting at the Oppenheimer Healthcare Conference 2025?
What is DiaMedica's (DMAC) lead drug candidate DM199 used for?
How can investors meet with DiaMedica (DMAC) management at the Oppenheimer conference?
What therapeutic areas does DiaMedica Therapeutics (DMAC) focus on?
Where has DiaMedica's (DMAC) DM199 treatment already been established?
